Last updated on November 2017

A randomized, double-blind, placebo-controoled, parallel-group, multicenter study to explore changes in subcutaneous adipose tissue and modulation of skin inflammation after 12 weeks of treatment with secukinumab in adult patients with moderate to severe plaque psoriasis.


Brief description of study

A randomized, double-blind, placebo-controoled, parallel-group, multicenter study to explore changes in subcutaneous adipose tissue and modulation of skin inflammation after 12 weeks of treatment with secukinumab in adult patients with moderate to severe plaque psoriasis.

Detailed Study Description

52 week study. Cosentyx vs placebo for 12 weeks, open label week 12-52.

Clinical Study Identifier: TX15975

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.